Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr;12(4):234-48.
doi: 10.1038/nrneurol.2016.27. Epub 2016 Mar 11.

HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment

Deanna Saylor  1 , Alex M Dickens  1 , Ned Sacktor  1 , Norman Haughey  1 , Barbara Slusher  1 , Mikhail Pletnikov  1 , Joseph L Mankowski  1 , Amanda Brown  1 , David J Volsky  2 , Justin C McArthur  1
Affiliations
Review

HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment

Deanna Saylor et al. Nat Rev Neurol. 2016 Apr.

Erratum in

Abstract

In the past two decades, several advancements have improved the care of HIV-infected individuals. Most importantly, the development and deployment of combination antiretroviral therapy (CART) has resulted in a dramatic decline in the rate of deaths from AIDS, so that people living with HIV today have nearly normal life expectancies if treated with CART. The term HIV-associated neurocognitive disorder (HAND) has been used to describe the spectrum of neurocognitive dysfunction associated with HIV infection. HIV can enter the CNS during early stages of infection, and persistent CNS HIV infection and inflammation probably contribute to the development of HAND. The brain can subsequently serve as a sanctuary for ongoing HIV replication, even when systemic viral suppression has been achieved. HAND can remain in patients treated with CART, and its effects on survival, quality of life and everyday functioning make it an important unresolved issue. In this Review, we describe the epidemiology of HAND, the evolving concepts of its neuropathogenesis, novel insights from animal models, and new approaches to treatment. We also discuss how inflammation is sustained in chronic HIV infection. Moreover, we suggest that adjunctive therapies--treatments targeting CNS inflammation and other metabolic processes, including glutamate homeostasis, lipid and energy metabolism--are needed to reverse or improve HAND-related neurological dysfunction.

PubMed Disclaimer

Conflict of interest statement

Competing interests statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1. Timeline of advances in neuro-AIDS research
Since the discovery of AIDS in 1981 and HIV in 1983, important advances have been made in research into and the prevention and treatment of HIV-associated neurocognitive disorder (HAND). AZT, azidothymidine; CART, combination antiretroviral therapy; HNRC, HIV Neurobehavioral Research Center; MACS, Multicenter AIDS Cohort Study; UCSD, University of California San Diego.
Figure 2
Figure 2. More-effective therapies have reduced the severity of HIV-associated the severity of HIV-associated neurocognitive disorders
Since the introduction of combination antiretroviral therapies (CARTs) in 1996, the proportion of HIV+ individuals with neurocognitive symptoms has remained unchanged, but the proportion of people with severe symptoms has declined so that HIV-associated dementia (HAD) is much less common and asymptomatic neurocognitive impairment (ANI) now accounts for the majority of cases. MND, mild neurocognitive disorder. Adapted from McArthur, J. C. et al. Ann. Neurol. 67, 699–714 (2010).
Figure 3
Figure 3. Neuropathogenic mechanisms that contribute to HIV-associated neurocognitive disorders
HIV-infected macrophages and microglial cells release neurotoxic viral proteins that trigger astrocyte activation, which results in increased glutamate release and reduced glutamate uptake. Elevated extracellular glutamate levels cause neuronal bioenergetic disturbances that lead to aberrant synaptodendritic pruning and neuronal injury. Moreover, systemic inflammation and microbial translocation products lead to microglial activation and increased production of chemokines and cytokines that contribute to neuronal injury. Adapted from Williams, D. W. et al. Curr. HIV Res. 12, 85–96 (2014).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Fauci AS, Marston HD. Ending the HIV-AIDS pandemic — follow the science. N Engl J Med. 2015;373:2197–2199. - PubMed
    1. Maschke M, et al. Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART) J Neurol Neurosurg Psychiatry. 2000;69:376–380. - PMC - PubMed
    1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. AIDSinfo. 2015 [online], https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.
    1. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807. - PMC - PubMed
    1. Antinori A, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789–1799. This article updated the research nosology for HIV-associated neurocognitive disorders. - PMC - PubMed

Publication types

MeSH terms

Grants and funding